Brainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Just Reported Increased Shorts

January 13, 2018 - By Richard Conner

 Brainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Just Reported Increased Shorts

The stock of Brainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) registered an increase of 2.48% in short interest. BCLI’s total short interest was 1.07M shares in January as published by FINRA. Its up 2.48% from 1.04 million shares, reported previously. With 50,900 shares average volume, it will take short sellers 21 days to cover their BCLI’s short positions. The short interest to Brainstorm Cell Therapeutics Incorporated’s float is 6.63%.

The stock decreased 1.92% or $0.07 during the last trading session, reaching $3.57. About 41,805 shares traded. Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) has risen 82.38% since January 13, 2017 and is uptrending. It has outperformed by 65.68% the S&P500.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, ParkinsonÂ’s disease, and others. The company has market cap of $67.27 million. The firm holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. It currently has negative earnings. The Company’s NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons.

More notable recent Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) news were published by: which released: “BrainStorm Cell Therapeutics’ (BCLI) CEO Chaim Lebovits on Q3 2017 Results …” on October 17, 2017, also with their article: “Brainstorm Cell Therapeutics Set To Begin Phase 3 In Amyotrophic Lateral Sclerosis” published on April 18, 2017, published: “BrainStorm Seeking Approval To Distribute NurOwn® in Canada” on February 21, 2017. More interesting news about Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) were released by: and their article: “BrainStorm Cell Therapeutics to Present at the 2017 Disruptive Growth Company …” published on September 27, 2017 as well as‘s news article titled: “BrainStorm Cell Therapeutics’ (BCLI) CEO Chaim Lebovits on Q2 2017 Results …” with publication date: August 16, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.